Stasis Ulcers Refractory to Therapy—Accelerated Healing by Treatment With Clopidogrel ± Dalteparin: A Preliminary Report

Abstract

Stasis ulcers are commonly the result of chronic venous insufficiency. We have recently assessed 15 patients with stasis ulcers that failed to heal after one year of routine wound care. All patients demonstrated a defect in hemostasis, and a biopsy revealed livido vasculitis. Eleven of fifteen patients were treated with clopidogrel and dalteparin, and 4 of 15 patients were treated with clopidogrel alone. Thirteen of fifteen patients (86.6%) completely healed within three months of starting antithrombotic therapy. Patients with stasis ulcers and chronic venous insufficiency who fail to heal with routine wound care should be subjected to biopsy, a procoagulant defect evaluation, and initiation of clopidogrel and dalteparin therapy if a defect is found.

References

National Committee for Clinical Laboratory Standards. H28P and H29P: Proposed guidelines for the one-stage prothrombin time and activated partial thrombopiastin time. Villanova, PA: National Committee for Clinical Laboratory Standards; 1988.

Reyes H. , Dearing L. , Bick RL , et al. Laboratory diagnosis of antiphospholipid syndrome, Clin Lab Med 1995;15:85.

Bick RL The antiphospholipid-thrombosis syndromes. Am J Clin Pathol 1993; 100:477.

Thiagarajan P. , Pengo V. , Shapiro S. The use of the dilute Russell Viper Venom Time for the diagnosis of lupus anticoagulants. Blood 1986;68:869.

Bell HG , Alton HG A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature 1954; 174:880.

Toschi V. , Motta A. , Costelli C. , et al. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998;29:1759.

Amengual O. , Atsui T. , Khamashta MA Specificity of ELISA for antibody to beta-2-glycoprotein I in patients with antiphospholipid syndrome. Brit J Rheumatol 1996;35:1239.

Ranch J. Tannenbaum M , Janoff AS Distinguishing plasma lupuis anticoaguiilants from other anti-factor antibodies using hexagonal (II) phase phospholipids . Thromb Haemost 1989:62:892.

Wolf M. Boyer-Neumann C. , Martinoli JL , et al. A new functional assay for human protein S activity using factor V as substrate. Thromb Haemost 1989;62:1144.

10.

Rellplate IED S assay. Total Protein S [package insert]. Parsippany, NJ: American Diagnostica; 1991.

11.

Rellplate IED S assay. Free Protein S [package insert]. Parsippany, NJ: American Diagnostica; 1991.

12.

ASSERA-Plate C4b-Binding Protein [package insert]. Parsippany, NJ: Diagnostica Stago; 1988.

13.

Stachrom Protein C Assay [package insert]. Parsippany, NJ: Diagnostica Stago; 1990.

14.

NANORID: Human Factor XIII Assay [package insert]. San Diego, CA: The Binding Site; 1994.

15.

Fickenachor K. , Aab A. , Stuber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991;65:535.

16.

IL Test—Antithrombin III: chromogenic substrate assay [package insert]. Lexington, MA: Instrumentation Laboratory; 1988.

17.

Mammen EF Ten years experience with the "sticky platelet syndrome." Clin Appl Thromb Hemost 1995;1:66.

18.

Dahlback B. , Carlsson M. Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90: 1004.

19.

Dahlback B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997;78:483.

20.

IL Test : PT-Fibrinogen. Instrumentation Laboratory, 1987

21.

IL Test : Plasminogen [package insert]. Instrumentation Laboratory ; 1988.

22.

Tissue Plasminogen Activator Inhibitor Assay [package insert) . Parsippany, NJ: American Diagnostica ; 1990.

23.

Tissue Plasminogen Activator Assay [package insert). Parsippany, NJ: American Diagnostica; 1990.

24.

Abildgaard U. , Larsen M. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res 1984;35: 257.

25.

Sandset M. , Abildgaard U. , Petterson A. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987:47:389.

26.

Poort S. , Rosendaal F. , Reitsma P. , et al. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996 ;88:3698.

27.

Frosst P. , Blom HJ , Milos R. , et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydro— folate reductase. Nat Genet 1995; 10:111.

28.

Cuba SC , Fonseca V. , Fink LM Hyperhomocysteinemia and thrombosis. Semin Thromb Hemost 1999;25:291.

29.

STACHROME Heparin: Colorimetric assay of unfractionated and low molecular weight heparins [package insert]. Parsippany, NJ: Diagnostica Stago; 1993.

30.

Caprie Steering Committee. A randomized trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 34:1129, 1996

31.

Wehrmacher WH , Messmore HL , Bick RL , et al. Ticlopidine and clopidogral: do they have direct vascular effects? Clin Appl Thromb Hemost 1997:3:225.

32.

Fareed J. Hoppensteadt D. Jeske W. , et al. The available low molecular weight heparin preparations are not the same. J Clin Appl Thromb Hemost 1997 ;3(suppl 1):38.

33.

Bick RL , Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost 1999:5:63.

34.

Bick RL Rice J. Long-term outpatient dulteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety—a preliminary report. Clin Appl Thromb Hemost 1999:5:67.